<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117050</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200136-586</org_study_id>
    <nct_id>NCT02117050</nct_id>
  </id_info>
  <brief_title>RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate</brief_title>
  <acronym>RESOunD</acronym>
  <official_title>RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment
      satisfaction in patients with relapsing forms of Multiple Sclerosis (MS)  who are currently
      being treated with, but are considering discontinuing treatment with Tecfidera™.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in Treatment satisfaction score determined by the global satisfaction sub-scale of the Treatment Satisfaction Questionnaire for Medication (TSQM [Version II]) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient-Determined Disease Steps Questionnaire (PDDS) score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Multiple Sclerosis Quality of Life-54 (MSQoL-54) score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TSQM (Version II) - Total score at Week 12 and Week 24</measure>
    <time_frame>Baseline, Week 12, and Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in  TSQM (Version II) - Medication effectiveness, side effects, and convenience subscale scores at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in TSQM (Version II) - Global satisfaction, medication effectiveness, side effects, and convenience subscale scores at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Work Productivity and Activity Impairment- General Health (WPAI-GH) questionnaire score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in number of Combined Unique Active (CUA) Lesions, New Time or Enlarging Constant 2 (T2) Lesions, and New Gadolinium Enhanced (Gd+) Time Constant 1 (T1) Lesions at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Rebif® via Rebidose® auto-injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rebif®</intervention_name>
    <description>Rebif® will be administered subcutaneously  three times a week at a dose of 8.8 to 44 mcg in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.</description>
    <arm_group_label>Rebif® via Rebidose® auto-injector</arm_group_label>
    <other_name>Rebif®</other_name>
    <other_name>interferon-beta-1a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  Diagnosis of relapsing form of MS

          -  Have declared a desire/plan to discontinue treatment with Tecfidera due to
             tolerability issues and/or lack of efficacy

          -  Expanded Disability Status Scale (EDSS) score 0 to 5.0 inclusive

          -  Other protocol defined inclusion criteria could apply

        Key exclusion Criteria:

          -  Pregnant or lactating

          -  Significant renal or hepatic impairment or other significant disease  that would
             compromise adherence and completion of the trial

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>EMD Serono Medical Information</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call EMD Serono Medical Information for information on recruiting sites</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>EMD Serono Medical Information</last_name>
      <phone>888-275-7376</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.narcoms.org/pdds</url>
    <description>The North American Research Committee on Multiple Sclerosis - Information about the PDDS Questionaire</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>April 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Rebif ®</keyword>
  <keyword>Tecfidera ™</keyword>
  <keyword>treatment change</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Dimethyl fumarate</mesh_term>
    <mesh_term>Interferon beta 1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
